On October 7, 1999, Pitts, William J.; Jadhav, Prabhakar K. published a patent.Name: tert-Butyl 4-((((benzyloxy)carbonyl)amino)methyl)benzoate The title of the patent was Preparation of pyrimidinylalkylphenylcarbonylaminopropanoates and related compounds as integrin antagonists. And the patent contained the following:
GT (T = integrin antagonist template; G = specified guanidine mimic), were prepared as antagonists of the αvβ3 integrin, the α2bβ3 integrin, and related cell surface adhesive protein receptors for the inhibition of cell adhesion, treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis. Thus, 2-[(S)-2,4,6-trimethylphenylsulfonylamino]-3-[4-[2-(2,4-diaminopyrimidin-6-yl)ethyl]phenylcarbonylamino]propionic acid trifluoroacetate was prepared in several steps from L-asparagine. In the αvβ3-vitronectin assay, tested title compounds showed IC50≤10 μM. The experimental process involved the reaction of tert-Butyl 4-((((benzyloxy)carbonyl)amino)methyl)benzoate(cas: 220851-46-7).Name: tert-Butyl 4-((((benzyloxy)carbonyl)amino)methyl)benzoate
The Article related to pyrimidinylalkylphenylcarbonylaminopropanoate preparation integrin antagonist, quinazolinylaminomethylphenylcarbonylaminopropanoate preparation integrin antagonist, cell adhesion inhibitor pyrimidine quinazoline triazine preparation and other aspects.Name: tert-Butyl 4-((((benzyloxy)carbonyl)amino)methyl)benzoate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics